Access to Document
- New Antidepressants_JELEN_Publishedonline23July2022_GREEN AAM (CC BY-NC-ND)Accepted author manuscript, 160 KBLicence: CC BY-NC-ND
Other files and links
TY - JOUR
T1 - New antidepressants: New day or false dawn
AU - Jelen, Luke A.
AU - Young, Allan H.
N1 - Funding Information: Allan Young: Employed by King's College London; Honorary Consultant SLaM (NHS UK). Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). No shareholdings in pharmaceutical companies. Funding Information: Luke Jelen: Employed by King's College London. Dr Luke A Jelen is supported by a Medical Research Council (MRC) Clinical Research Training Fellowship (MR/T028084/1). Funding Information: This report represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London . The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. Funding Information: Professor Allan Young : Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage, Novartis. Consultant to Johnson & Johnson. Consultant to Livanova. Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.” Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants.” Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD).” UK Chief Investigator for Novartis MDD study MIJ821A12201. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). No shareholdings in pharmaceutical companies.
PY - 2022/10
Y1 - 2022/10
UR - http://www.scopus.com/inward/record.url?scp=85134746070&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.euroneuro.2022.07.004
DO - https://doi.org/10.1016/j.euroneuro.2022.07.004
M3 - Article
SN - 0924-977X
VL - 63
SP - 1
EP - 3
JO - European Neuropsychopharmacology
JF - European Neuropsychopharmacology